• The CREATE-X study:
    • Randomly assigned 910 patients:
      • With HER2 negative breast cancer and residual disease after undergoing neoadjuvant chemotherapy to:
        • Standard postsurgical treatment and capecitabine or placebo
    • The primary end point was:
      • Disease-free survival (DFS)
    • Secondary end points included:
      • Overall survival (OS)
    • DFS was longer in the capecitabine group than in the control group:
      • 74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years
    • Among patients with triple-negative disease:
      • DFS was 69.8% in the capecitabine group versus 56.1% in the control group
      • The OS rate was 78.8% versus 70.3%
  • Residual disease after completion of neoadjuvant chemotherapy:
    • Is associated with worse outcomes
  • References:
    • Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Eng J Med. 2017;376(22):2147-2159.
    • Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049-1060.

#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncology #BreastCancer #CASO #CenterforAdvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s